Premium
Xeris Biopharma Holdings Inc (XERS)
NASDAQ
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-03 | Ms. Marla S. PerskyIndependent Chairman | -15,50k | 91,43k | Automatic Disposition | 5,90 | 132,87k | -10,45% |
| 2026-06-04 | Ms. Dawn HalkuffIndependent Director | -20,00k | 121,89k | Automatic Disposition | 6,09 | 100,41k | -16,61% |
| 2026-06-04 | Dr. Barbar-Jean Anne Bormann-KennedyIndependent Director | -16,00k | 97,51k | Automatic Disposition | 6,09 | 126,50k | -11,23% |
| 2026-06-04 | Mr. John H. JohnsonIndependent Non-Executive Director | -15,00k | 91,42k | Automatic Disposition | 6,09 | 683,08k | -2,15% |
| 2026-06-01 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 100,98k | Automatic Disposition | 6,06 | 681,88k | -2,39% |
| 2026-05-01 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 103,81k | Vente | 6,23 | 698,55k | -2,33% |
| 2026-04-01 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 99,86k | Automatic Disposition | 5,99 | 715,21k | -2,28% |
| 2026-03-30 | Mr. James Aloysius BradyIndependent Director | -10,83k | 60,04k | Automatic Disposition | 5,54 | 89,17k | -10,83% |
| 2026-03-12 | Mr. Kevin McCullochPresident & COO | 48,90k | 199,99k | Derivative Exercise and Retained Stock | 3,94 - 4,09 | 1,80M | 2,79% |
| 2026-03-05 | Mr. Steven M. PieperCFO | 41,93k | 197,31k | Derivative Exercise and Retained Stock | 4,09 - 5,93 | 1,41M | 3,07% |
| 2026-03-02 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 104,09k | Automatic Disposition | 6,24 - 7,06 | 731,88k | -2,23% |
| 2026-02-24 | Dr. Anh T. NguyenChief Medical Officer | -29,30k | 201,58k | Sale to Issuer | 6,88 | 80,94k | -26,58% |
| 2026-01-31 | Mr. Kevin McCullochPresident & COO | -126,06k | 927,82k | Sale to Issuer | 7,36 | 1,75M | -6,71% |
| 2026-01-31 | Mr. John P. ShannonCEO & Director | -340,51k | 2,51M | Sale to Issuer | 7,36 | 1,51M | -18,43% |
| 2026-01-31 | Mr. Steven M. PieperCFO | -205,53k | 1,51M | Sale to Issuer | 7,36 | 1,37M | -13,07% |
| 2026-02-02 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 124,15k | Automatic Disposition | 7,45 | 748,55k | -2,18% |
| 2026-01-31 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -169,56k | 1,25M | Sale to Issuer | 7,36 | 748,55k | -18,47% |
| 2026-01-08 | Mr. Kevin McCullochPresident & COO | -15,00k | 120,00k | Automatic Disposition | 8,00 | 1,71M | -0,87% |
| 2026-01-05 | Mr. John P. ShannonCEO & Director | 92,30k | 150,00k | Derivative Exercise and Retained Stock | 1,55 - 3,94 | 1,08M | 9,34% |
| 2026-01-05 | Mr. John P. ShannonCEO & Director | -24,91k | 176,26k | Automatic Disposition | 7,08 | 1,08M | -2,25% |
| 2026-01-02 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 123,78k | Automatic Disposition | 7,43 | 506,44k | -3,19% |
| 2025-12-19 | Mr. John H. JohnsonIndependent Non-Executive Director | -135,40k | 977,02k | Vente | 7,22 | 648,08k | -17,28% |
| 2025-12-12 | Dr. Barbar-Jean Anne Bormann-KennedyIndependent Director | -15,00k | 106,41k | Automatic Disposition | 7,09 | 92,50k | -13,95% |
| 2025-12-01 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 116,78k | Automatic Disposition | 7,01 | 518,51k | -3,11% |
| 2025-11-14 | Mr. John P. ShannonCEO & Director | 87,10k | 135,01k | Derivative Exercise and Retained Stock | 1,55 | 1,01M | 9,40% |
| 2025-11-13 | Mr. John P. ShannonCEO & Director | -8,97k | 53,02k | Derivative Exercise and Sale | 1,55 - 7,46 | 1,01M | - |
| 2025-11-13 | Mr. John P. ShannonCEO & Director | -14,27k | 106,48k | Automatic Disposition | 7,46 | 1,01M | -1,39% |
| 2025-11-11 | Ms. Beth P. HechtChief Legal Officer & Corporate Secretary | -16,67k | 123,30k | Automatic Disposition | 7,40 | 535,18k | -3,02% |
| 2025-10-02 | Mr. Kevin McCullochPresident & COO | -733,00 | 6,09k | Sale to Issuer | 8,31 | 1,73M | -0,04% |
| 2025-09-11 | Mr. Kevin McCullochPresident & COO | -2,00k | 0,00 | Other Disposition | - | 1,73M | -0,12% |
| 2025-09-11 | Ms. Marla S. PerskyIndependent Chairman | -15,50k | 119,61k | Automatic Disposition | 7,72 | 98,37k | -13,61% |
| 2025-08-28 | Dr. Jeffrey W. ShermanInitié | 4,81k | 32,02k | Derivative Exercise and Retained Stock | 6,66 | 174,59k | 2,83% |
| 2025-08-28 | Dr. Jeffrey W. ShermanInitié | -42,23k | 53,25k | Derivative Exercise and Sale | 6,66 - 7,92 | 174,59k | - |
| 2025-08-13 | Mr. John H. JohnsonIndependent Non-Executive Director | -107,50k | 786,46k | Vente | 7,32 | 783,48k | -12,07% |
| 2025-08-12 | Ms. Dawn HalkuffIndependent Director | -42,50k | 309,23k | Vente | 7,28 | 70,41k | -37,64% |
| 2025-08-01 | Mr. Kevin McCullochPresident & COO | -14,65k | 78,82k | Sale to Issuer | 5,38 | 1,73M | -0,84% |
| 2025-08-01 | Mr. John P. ShannonCEO & Director | -36,92k | 198,62k | Sale to Issuer | 5,38 | 940,76k | -3,78% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
